YM155 sensitizes triple‐negative breast cancer to membrane‐bound TRAIL through p38 MAPK‐ and CHOP‐mediated DR5 upregulation
Because available treatments have limited efficacy in triple‐negative breast cancer (TNBC), the identification of new therapeutic strategies to improve patients' outcome is urgently needed. In our study, we investigated the effects of the administration of the small molecule selective survivin...
Saved in:
Published in | International journal of cancer Vol. 136; no. 2; pp. 299 - 309 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
15.01.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Because available treatments have limited efficacy in triple‐negative breast cancer (TNBC), the identification of new therapeutic strategies to improve patients' outcome is urgently needed. In our study, we investigated the effects of the administration of the small molecule selective survivin suppressant YM155, alone or in association with CD34+ cells transduced with a replication‐deficient adenovirus encoding the human tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) gene (CD34‐TRAIL+ cells), in three TNBC cell models. YM155 exposure significantly impaired TNBC cell growth and selectively modulated survivin expression at both mRNA and protein level. In addition, co‐culturing YM155‐treated TNBC cells with CD34‐TRAIL+ cells resulted in markedly increased cytotoxic effect and apoptotic response in comparison with single treatments. Such a chemosensitizing effect was observed only in TNBC cells inherently expressing DR5 and relied on the ability of YM155 to upregulate DR5 expression through a p38 MAPK‐ and CHOP‐dependent mechanism. YM155/CD34‐TRAIL+ combination also showed a significant inhibitory effect on the growth of DR5‐expressing TNBC cells following xenotransplantation into NOD/SCID mice, in the absence of toxicity. Overall, our data (i) provide, for the first time, evidence that YM155 sensitizes TNBC cells to CD34‐TRAIL+ cells‐induced apoptosis by a mechanism involving the downregulation of survivin and the simultaneous p38 MAPK‐ and CHOP‐mediated upregulation of DR5, and (ii) suggest the combination of YM155 with TRAIL‐armed CD34+ progenitor cells as a promising therapeutic option for patients with TNBC expressing DR5.
What's new?
In this study, a new combined treatment based on the use of the survivin inhibitor YM155 and CD34+ cells transduced with an adenovirus encoding the human TRAIL gene (CD34‐TRAIL+ cells) produced synergistic effects in experimental models of triple‐negative breast cancer (TNBC). Such antitumor effect relied on the ability of YM155 to up‐regulate the death receptor DR5 through a p38 MAPK‐ and CHOP‐dependent mechanism and was selectively observed in TNBC models inherently expressing DR5. The findings provide a molecular basis for a rational combination to be clinically exploited in TNBC and suggest DR5 expression as a possible marker for patient selection. |
---|---|
AbstractList | Because available treatments have limited efficacy in triple‐negative breast cancer (TNBC), the identification of new therapeutic strategies to improve patients' outcome is urgently needed. In our study, we investigated the effects of the administration of the small molecule selective survivin suppressant YM155, alone or in association with CD34+ cells transduced with a replication‐deficient adenovirus encoding the human tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) gene (CD34‐TRAIL+ cells), in three TNBC cell models. YM155 exposure significantly impaired TNBC cell growth and selectively modulated survivin expression at both mRNA and protein level. In addition, co‐culturing YM155‐treated TNBC cells with CD34‐TRAIL+ cells resulted in markedly increased cytotoxic effect and apoptotic response in comparison with single treatments. Such a chemosensitizing effect was observed only in TNBC cells inherently expressing DR5 and relied on the ability of YM155 to upregulate DR5 expression through a p38 MAPK‐ and CHOP‐dependent mechanism. YM155/CD34‐TRAIL+ combination also showed a significant inhibitory effect on the growth of DR5‐expressing TNBC cells following xenotransplantation into NOD/SCID mice, in the absence of toxicity. Overall, our data (i) provide, for the first time, evidence that YM155 sensitizes TNBC cells to CD34‐TRAIL+ cells‐induced apoptosis by a mechanism involving the downregulation of survivin and the simultaneous p38 MAPK‐ and CHOP‐mediated upregulation of DR5, and (ii) suggest the combination of YM155 with TRAIL‐armed CD34+ progenitor cells as a promising therapeutic option for patients with TNBC expressing DR5.
What's new?
In this study, a new combined treatment based on the use of the survivin inhibitor YM155 and CD34+ cells transduced with an adenovirus encoding the human TRAIL gene (CD34‐TRAIL+ cells) produced synergistic effects in experimental models of triple‐negative breast cancer (TNBC). Such antitumor effect relied on the ability of YM155 to up‐regulate the death receptor DR5 through a p38 MAPK‐ and CHOP‐dependent mechanism and was selectively observed in TNBC models inherently expressing DR5. The findings provide a molecular basis for a rational combination to be clinically exploited in TNBC and suggest DR5 expression as a possible marker for patient selection. Because available treatments have limited efficacy in triple-negative breast cancer (TNBC), the identification of new therapeutic strategies to improve patients' outcome is urgently needed. In our study, we investigated the effects of the administration of the small molecule selective survivin suppressant YM155, alone or in association with CD34+ cells transduced with a replication-deficient adenovirus encoding the human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene (CD34-TRAIL+ cells), in three TNBC cell models. YM155 exposure significantly impaired TNBC cell growth and selectively modulated survivin expression at both mRNA and protein level. In addition, co-culturing YM155-treated TNBC cells with CD34-TRAIL+ cells resulted in markedly increased cytotoxic effect and apoptotic response in comparison with single treatments. Such a chemosensitizing effect was observed only in TNBC cells inherently expressing DR5 and relied on the ability of YM155 to upregulate DR5 expression through a p38 MAPK- and CHOP-dependent mechanism. YM155/CD34-TRAIL+ combination also showed a significant inhibitory effect on the growth of DR5-expressing TNBC cells following xenotransplantation into NOD/SCID mice, in the absence of toxicity. Overall, our data (i) provide, for the first time, evidence that YM155 sensitizes TNBC cells to CD34-TRAIL+ cells-induced apoptosis by a mechanism involving the downregulation of survivin and the simultaneous p38 MAPK- and CHOP-mediated upregulation of DR5, and (ii) suggest the combination of YM155 with TRAIL-armed CD34+ progenitor cells as a promising therapeutic option for patients with TNBC expressing DR5. Because available treatments have limited efficacy in triple-negative breast cancer (TNBC), the identification of new therapeutic strategies to improve patients' outcome is urgently needed. In our study, we investigated the effects of the administration of the small molecule selective survivin suppressant YM155, alone or in association with CD34+ cells transduced with a replication-deficient adenovirus encoding the human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene (CD34-TRAIL+ cells), in three TNBC cell models. YM155 exposure significantly impaired TNBC cell growth and selectively modulated survivin expression at both mRNA and protein level. In addition, co-culturing YM155-treated TNBC cells with CD34-TRAIL+ cells resulted in markedly increased cytotoxic effect and apoptotic response in comparison with single treatments. Such a chemosensitizing effect was observed only in TNBC cells inherently expressing DR5 and relied on the ability of YM155 to upregulate DR5 expression through a p38 MAPK- and CHOP-dependent mechanism. YM155/CD34-TRAIL+ combination also showed a significant inhibitory effect on the growth of DR5-expressing TNBC cells following xenotransplantation into NOD/SCID mice, in the absence of toxicity. Overall, our data (i) provide, for the first time, evidence that YM155 sensitizes TNBC cells to CD34-TRAIL+ cells-induced apoptosis by a mechanism involving the downregulation of survivin and the simultaneous p38 MAPK- and CHOP-mediated upregulation of DR5, and (ii) suggest the combination of YM155 with TRAIL-armed CD34+ progenitor cells as a promising therapeutic option for patients with TNBC expressing DR5. What's new? In this study, a new combined treatment based on the use of the survivin inhibitor YM155 and CD34+ cells transduced with an adenovirus encoding the human TRAIL gene (CD34-TRAIL+ cells) produced synergistic effects in experimental models of triple-negative breast cancer (TNBC). Such antitumor effect relied on the ability of YM155 to up-regulate the death receptor DR5 through a p38 MAPK- and CHOP-dependent mechanism and was selectively observed in TNBC models inherently expressing DR5. The findings provide a molecular basis for a rational combination to be clinically exploited in TNBC and suggest DR5 expression as a possible marker for patient selection. |
Author | Carlo‐Stella, Carmelo Daidone, Maria Grazia De Cesare, Michelandrea Locatelli, Silvia L. Lopergolo, Alessia Zaffaroni, Nadia Campi, Elisa Pennati, Marzia Sbarra, Stefania Gianni, Alessandro M. |
Author_xml | – sequence: 1 givenname: Marzia surname: Pennati fullname: Pennati, Marzia organization: Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 2 givenname: Stefania surname: Sbarra fullname: Sbarra, Stefania organization: Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 3 givenname: Michelandrea surname: De Cesare fullname: De Cesare, Michelandrea organization: Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 4 givenname: Alessia surname: Lopergolo fullname: Lopergolo, Alessia organization: Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 5 givenname: Silvia L. surname: Locatelli fullname: Locatelli, Silvia L. organization: Humanitas Cancer Center ‐ Humanitas Clinical and Research Center – sequence: 6 givenname: Elisa surname: Campi fullname: Campi, Elisa organization: Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 7 givenname: Maria Grazia surname: Daidone fullname: Daidone, Maria Grazia organization: Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 8 givenname: Carmelo surname: Carlo‐Stella fullname: Carlo‐Stella, Carmelo organization: Humanitas Cancer Center ‐ Humanitas Clinical and Research Center – sequence: 9 givenname: Alessandro M. surname: Gianni fullname: Gianni, Alessandro M. organization: Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 10 givenname: Nadia surname: Zaffaroni fullname: Zaffaroni, Nadia organization: Fondazione IRCCS Istituto Nazionale dei Tumori |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24866585$$D View this record in MEDLINE/PubMed |
BookMark | eNo9kclOwzAURS1URAdY8APIEuu0HmLHWVZlaKEIhGDBKnKcl5KqdYKTgMoKiR_gG_kSTBlW70r36E23jzq2tIDQISVDSggbFUszZCqO-Q7qURJHAWFUdFDPeySIKJdd1K_rJSGUChLuoS4LlZRCiR56f7iiQuAabF00xSvUuHFFtYLPtw8LC90Uz4BTB7pusNHWgMNNidewTp2231BatjbDd7fj2Rw3j65sF4-44gpfjW8uvY21dyfT6xuv15AVuoEMn9wK3FYOFu3KDyjtPtrN9aqGg986QPdnp3eTaTC_Pp9NxvPAhDHhgRQkBQVK6DhkJlNZCJGmyggGRrKIyJyTnCl_umEiB8h1RmQGjKY6Sg2XfICOf_pWrnxqoW6SZdk660cmVNIo5hGToaeOfqk29SsnlSvW2m2Sv595YPQDvBQr2Pz7lCTfYSQ-jGQbRjK7mGwF_wLxNoDf |
CitedBy_id | crossref_primary_10_1080_10286020_2018_1464560 crossref_primary_10_3390_cells9102231 crossref_primary_10_3390_md13116884 crossref_primary_10_1021_acs_jmedchem_6b00943 crossref_primary_10_1007_s12272_018_01103_y crossref_primary_10_1186_s12885_019_5713_2 crossref_primary_10_1002_tox_23372 crossref_primary_10_1039_c5pp00438a crossref_primary_10_3390_ijms22189722 crossref_primary_10_3892_ijo_2015_3204 crossref_primary_10_1016_j_phymed_2019_152950 crossref_primary_10_3390_cancers12051080 crossref_primary_10_18632_oncotarget_4121 crossref_primary_10_1038_s41401_019_0253_5 crossref_primary_10_4196_kjpp_2017_21_4_397 crossref_primary_10_18632_oncotarget_11137 crossref_primary_10_3390_cells9081760 crossref_primary_10_1158_1078_0432_CCR_15_2170 crossref_primary_10_3390_cancers11081087 crossref_primary_10_1016_j_bcp_2016_11_024 crossref_primary_10_1038_s41598_020_71157_w crossref_primary_10_3389_fimmu_2017_01612 crossref_primary_10_3892_ijo_2018_4562 crossref_primary_10_3389_fimmu_2021_699746 |
ContentType | Journal Article |
Copyright | 2014 UICC 2014 UICC. |
Copyright_xml | – notice: 2014 UICC – notice: 2014 UICC. |
DBID | CGR CUY CVF ECM EIF NPM 7T5 7TO 7U9 H94 K9. |
DOI | 10.1002/ijc.28993 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts |
DatabaseTitleList | MEDLINE AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1097-0215 |
EndPage | 309 |
ExternalDocumentID | 3474432531 24866585 IJC28993 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Associazione Italiana per la Ricerca sul Cancro (AIRC) funderid: MCO‐9998 |
GroupedDBID | --- -~X .3N .GA 05W 0R~ 10A 1L6 1OB 1OC 1ZS 24P 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABIJN ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN F00 F01 F04 F5P FUBAC G-S G.N GNP GODZA H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWI RX1 RYL SUPJJ TEORI UB1 UDS V2E V8K V9Y W2D W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WWO WXI WXSBR XG1 XPP XV2 ZZTAW ~IA ~WT ACSMX ACXME CGR CUY CVF ECM EIF NPM 7T5 7TO 7U9 H94 K9. |
ID | FETCH-LOGICAL-c4903-650be8e85a942cd8d4e7a18c52ec62706f30f28215c25feefad06de21ba7bc363 |
IEDL.DBID | DR2 |
ISSN | 0020-7136 |
IngestDate | Fri Sep 13 07:00:17 EDT 2024 Thu May 23 23:19:48 EDT 2024 Sat Aug 24 00:59:37 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | survivin triple-negative breast cancer TRAIL YM155 death receptors |
Language | English |
License | 2014 UICC. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4903-650be8e85a942cd8d4e7a18c52ec62706f30f28215c25feefad06de21ba7bc363 |
Notes | M.P. and S.S. contributed equally to this work * |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.28993 |
PMID | 24866585 |
PQID | 1617937264 |
PQPubID | 105430 |
PageCount | 11 |
ParticipantIDs | proquest_journals_1617937264 pubmed_primary_24866585 wiley_primary_10_1002_ijc_28993_IJC28993 |
PublicationCentury | 2000 |
PublicationDate | 15 January 2015 |
PublicationDateYYYYMMDD | 2015-01-15 |
PublicationDate_xml | – month: 01 year: 2015 text: 15 January 2015 day: 15 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Hoboken |
PublicationTitle | International journal of cancer |
PublicationTitleAlternate | Int J Cancer |
PublicationYear | 2015 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2010; 31 2009; 41 2013; 4 2013; 22 2013; 43 2013; 24 2011; 82 2004; 25 2006; 17 2006; 5 2010; 285 2011; 32 2011; 12 2011; 56 2000; 275 2008; 6 2007; 30 2011; 39 2012; 11 2005; 24 2005; 25 2007; 28 2004; 11 2012; 70 2011; 102 2012; 3 2004; 279 2013; 34 2006; 27 2008; 29 2010; 115 1988; 48 2013; 332 2013; 431 1997; 17 2008; 68 2008; 610 2012; 25 2012; 136 2012; 23 1992; 23 2007; 67 2001; 14 2012; 118 2011; 286 2006; 103 2011; 164 2012; 40 |
References_xml | – volume: 17 start-page: 141 year: 1997 end-page: 3 article-title: KILLER/DR5 is a DNA damage‐inducible p53‐regulated death receptor gene publication-title: Nat Genet – volume: 102 start-page: 614 year: 2011 end-page: 21 article-title: Broad spectrum and potent antitumor activities of YM155, a novel small‐molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models publication-title: Cancer Sci – volume: 136 start-page: 457 year: 2012 end-page: 67 article-title: Surveillance of spontaneous breast cancer metastasis by TRAIL‐expressing CD34 cells in a xenograft model publication-title: Breast Cancer Res Treat – volume: 279 start-page: 35829 year: 2004 end-page: 39 article-title: Deficient tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL‐induced apoptosis publication-title: J Biol Chem – volume: 11 start-page: 915 year: 2004 end-page: 23 article-title: Downregulation of Bcl‐2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL‐induced apoptosis publication-title: Cell Death Differ – volume: 24 start-page: 260 year: 2013 end-page: 9 article-title: Nutlin‐3, a small‐molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL‐induced apoptosis through p53‐mediated PUMA upregulation and ROS‐mediated DR5 upregulation publication-title: Anticancer Drugs – volume: 279 start-page: 45495 year: 2004 end-page: 502 article-title: CHOP is involved in endoplasmic reticulum stress‐induced apoptosis by enhancing DR5 expression in human carcinoma cells publication-title: J Biol Chem – volume: 3 start-page: 833 year: 2012 end-page: 42 article-title: Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells publication-title: Oncotarget – volume: 32 start-page: 723 year: 2011 end-page: 31 article-title: Lipid raft‐dependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid‐induced apoptosis in gastric cancer cells publication-title: Carcinogenesis – volume: 40 start-page: 1058 year: 2012 end-page: 65 article-title: Gomisin N enhances TRAIL‐induced apoptosis via reactive oxygen species‐mediated up‐regulation of death receptors 4 and 5 publication-title: Int J Oncol – volume: 67 start-page: 8014 year: 2007 end-page: 21 article-title: YM155, a novel small‐molecule survivin suppressant, induces regression of established human hormone‐refractory prostate tumor xenografts publication-title: Cancer Res – volume: 41 start-page: 362 year: 2009 end-page: 9 article-title: Tunicamycin enhances TRAIL‐induced apoptosis by inhibition of cyclin D1 and the subsequent downregulation of survivin publication-title: Exp Mol Med – volume: 82 start-page: 216 year: 2011 end-page: 26 article-title: Sorafenib induces apoptotic cell death in human non‐small cell lung cancer cells by down‐regulating mammalian target of rapamycin (mTOR)‐dependent survivin expression publication-title: Biochem Pharmacol – volume: 103 start-page: 10283 year: 2006 end-page: 8 article-title: Death‐receptor activation halts clathrin‐dependent endocytosis publication-title: Proc Natl Acad Sci USA – volume: 28 start-page: 2114 year: 2007 end-page: 21 article-title: Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL‐induced cytotoxicity by quercetin in non‐small cell lung cancer cells publication-title: Carcinogenesis – volume: 23 start-page: vi56 issue: Suppl 6 year: 2012 end-page: vi65 article-title: Emerging targeted therapies in triple‐negative breast cancer publication-title: Ann Oncol – volume: 285 start-page: 35418 year: 2010 end-page: 27 article-title: Gossypol induces death receptor‐5 through activation of the ROS‐ERK‐CHOP pathway and sensitizes colon cancer cells to TRAIL publication-title: J Biol Chem – volume: 5 start-page: 179 year: 2006 end-page: 86 article-title: Silencing of survivin gene by small interfering RNAs produces supra‐additive growth suppression in combination with 17‐allylamino‐17‐demethoxygeldanamycin in human prostate cancer cells publication-title: Mol Cancer Ther – volume: 286 start-page: 1134 year: 2011 end-page: 46 article-title: Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species‐ and ERK‐dependent up‐regulation of death receptors, p53, and Bax publication-title: J Biol Chem – volume: 56 start-page: 285 year: 2011 end-page: 90 article-title: Triple negative breast cancer: adjuvant chemotherapy effect on survival publication-title: Adv Med Sci – volume: 24 start-page: 2601 year: 2013 end-page: 6 article-title: A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non‐small‐cell lung cancer publication-title: Ann Oncol – volume: 164 start-page: 1433 year: 2011 end-page: 44 article-title: Methyl jasmonate down‐regulates survivin expression and sensitizes colon carcinoma cells towards TRAIL‐induced cytotoxicity publication-title: Br J Pharmacol – volume: 275 start-page: 32208 year: 2000 end-page: 13 article-title: The tumor necrosis factor‐related apoptosis‐inducing ligand receptors TRAIL‐R1 and TRAIL‐R2 have distinct cross‐linking requirements for initiation of apoptosis and are non‐redundant in JNK activation publication-title: J Biol Chem – volume: 43 start-page: 1291 year: 2013 end-page: 300 article-title: CAPE promotes TRAIL‐induced apoptosis through the upregulation of TRAIL receptors via activation of p38 and suppression of JNK in SK‐Hep1 hepatocellular carcinoma cells publication-title: Int J Oncol – volume: 27 start-page: 1768 year: 2006 end-page: 77 article-title: Sulforaphane enhances TRAIL‐induced apoptosis through the induction of DR5 expression in human osteosarcoma cells publication-title: Carcinogenesis – volume: 30 start-page: 679 year: 2007 end-page: 87 article-title: Fenretinide up‐regulates DR5/TRAIL‐R2 expression via the induction of the transcription factor CHOP and combined treatment with fenretinide and TRAIL induces synergistic apoptosis in colon cancer cell lines publication-title: Int J Oncol – volume: 17 start-page: 1225 year: 2006 end-page: 40 article-title: Antitumor activity of human CD34+ cells expressing membrane‐bound tumor necrosis factor‐related apoptosis‐inducing ligand publication-title: Hum Gene Ther – volume: 118 start-page: 3128 year: 2012 end-page: 34 article-title: A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B‐cell lymphoma publication-title: Cancer – volume: 24 start-page: 6877 year: 2005 end-page: 89 article-title: Sodium butyrate sensitizes human glioma cells to TRAIL‐mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP publication-title: Oncogene – volume: 14 start-page: 29 year: 2001 end-page: 36 article-title: SB203580, a specific inhibitor of p38‐MAPK pathway, is a new reversal agent of P‐glycoprotein mediated multidrug resistance publication-title: Eur J Pharm Sci – volume: 25 start-page: 5404 year: 2005 end-page: 16 article-title: Transcription factor NF‐kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1 publication-title: Mol Cell Biol – volume: 115 start-page: 2231 year: 2010 end-page: 40 article-title: Human CD34+ cells engineered to express membrane‐bound tumor necrosis factor‐related apoptosis‐inducing ligand target both tumor cells and tumor vasculature publication-title: Blood – volume: 610 start-page: 100 year: 2008 end-page: 11 article-title: Anticancer cell therapy with TRAIL‐armed CD34+ progenitor cells publication-title: Adv Exp Med Biol – volume: 25 start-page: 319 year: 2012 end-page: 23 article-title: Triple negative breast cancer: a brief review of its characteristics and treatment options publication-title: J Pharm Pract – volume: 22 start-page: 986 year: 2013 end-page: 92 article-title: Biological subtypes of triple‐negative breast cancer are associated with distinct morphological changes and clinical behaviour publication-title: Breast – volume: 11 start-page: 3 year: 2012 end-page: 13 article-title: TRAIL signaling and synergy mechanisms used in TRAIL‐based combination therapies publication-title: Mol Cancer Ther – volume: 68 start-page: 5273 year: 2008 end-page: 81 article-title: Molecular dependence of estrogen receptor‐negative breast cancer on a notch‐survivin signaling axis publication-title: Cancer Res – volume: 4 start-page: e471 year: 2013 article-title: Salirasib sensitizes hepatocarcinoma cells to TRAIL‐induced apoptosis through DR5 and survivin‐dependent mechanisms publication-title: Cell Death Dis – volume: 25 start-page: 1813 year: 2004 end-page: 20 article-title: Sodium butyrate sensitizes TRAIL‐mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells publication-title: Carcinogenesis – volume: 39 start-page: 569 year: 2011 end-page: 75 article-title: YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer publication-title: Int J Oncol – volume: 31 start-page: 367 year: 2010 end-page: 75 article-title: Capsaicin sensitizes malignant glioma cells to TRAIL‐mediated apoptosis via DR5 upregulation and survivin downregulation publication-title: Carcinogenesis – volume: 431 start-page: 354 year: 2013 end-page: 9 article-title: Lipoxygenase inhibitor MK886 potentiates TRAIL‐induced apoptosis through CHOP‐ and p38 MAPK‐mediated up‐regulation of death receptor 5 in malignant glioma publication-title: Biochem Biophys Res Commun – volume: 34 start-page: 1918 year: 2013 end-page: 28 article-title: Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c‐FLIP downregulation publication-title: Carcinogenesis – volume: 332 start-page: 225 year: 2013 end-page: 28 article-title: Targeting survivin in cancer publication-title: Cancer Lett – volume: 12 start-page: 719 year: 2011 end-page: 24 article-title: Impact of triple negative phenotype on prognosis and early onset of breast cancer in Iranian females publication-title: Asian Pac J Cancer Prev – volume: 48 start-page: 117 year: 1988 end-page: 21 article-title: In vitro pharmacodynamics of 1‐β‐d‐arabinofuranosylcytosine: synergy of antitumor activity with cis‐diamminedichloroplatinum (II) publication-title: Cancer Res – volume: 6 start-page: 1861 year: 2008 end-page: 71 article-title: TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5 publication-title: Mol Cancer Res – volume: 29 start-page: 1734 year: 2008 end-page: 41 article-title: Hypoxia‐inducible factor‐2alpha regulates the expression of TRAIL receptor DR5 in renal cancer cells publication-title: Carcinogenesis – volume: 23 start-page: 87 year: 1992 end-page: 95 article-title: Characterization of two human mammary carcinomas, MT‐1 and MT‐3, suitable for in vivo testing of ether lipids and their derivatives publication-title: Breast Cancer Res Treat – volume: 70 start-page: 373 year: 2012 end-page: 80 article-title: Pharmacokinetics of sepantronium bromide (YM155), a small‐molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment publication-title: Cancer Chemother Pharmacol |
SSID | ssj0011504 |
Score | 2.3353221 |
Snippet | Because available treatments have limited efficacy in triple‐negative breast cancer (TNBC), the identification of new therapeutic strategies to improve... Because available treatments have limited efficacy in triple-negative breast cancer (TNBC), the identification of new therapeutic strategies to improve... |
SourceID | proquest pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 299 |
SubjectTerms | Adenoviruses Animals Apoptosis Apoptosis - drug effects Blotting, Western Breast cancer Cancer Cell Membrane - metabolism Cell Proliferation - drug effects death receptors Female Flow Cytometry Gene Expression Regulation, Neoplastic - drug effects Humans Imidazoles - pharmacology Inhibitor of Apoptosis Proteins - antagonists & inhibitors Inhibitor of Apoptosis Proteins - metabolism Medical research Mice Mice, Inbred NOD Mice, SCID Naphthoquinones - pharmacology p38 Mitogen-Activated Protein Kinases - metabolism Reactive Oxygen Species - metabolism Receptors, TNF-Related Apoptosis-Inducing Ligand - metabolism Rodents survivin TNF-Related Apoptosis-Inducing Ligand - metabolism TRAIL Transcription Factor CHOP - metabolism Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - metabolism Triple Negative Breast Neoplasms - pathology triple‐negative breast cancer Tumor Cells, Cultured Xenograft Model Antitumor Assays YM155 |
Title | YM155 sensitizes triple‐negative breast cancer to membrane‐bound TRAIL through p38 MAPK‐ and CHOP‐mediated DR5 upregulation |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fijc.28993 https://www.ncbi.nlm.nih.gov/pubmed/24866585 https://www.proquest.com/docview/1617937264/abstract/ |
Volume | 136 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3NTtwwEMet1R4QF0qhtEsB-cChl-wmcZwP9bTaghZKWrQCaZEqRbYzRrQirHazF06VeAGekSfpTD4WgXqoerPkRHI0Y_s_zvg3jB0SQy0GdF43T6wTaOE5cSjBEcrKHJRrhKULzum3cHwZnE7ltMM-t3dhaj7E6sCNZka1XtMEV3oxeIaG3vw0fYoWiPRJID0SRJMVOoqETkNgdh0MxMKWKuT6g9Wbf1OVL0Vqtcscv2E_2vHVySW_-stS9839K3Tjf37AJtto1Ccf1u7ylnWg2GJrafN_fZs9XKW48_MFZbWXN_ew4OWcTuKffj8WcF0xwrmmNPaSG3KXOS_v-C3c4jAKekhTkSZ-MRmenPGmAhCfiZinw_Ov2M0V9o7G38-xXV1ZQbnLv0wkX87mcN0UEnvHLo-PLkZjpynT4JggcYWDGk8D2luqJPBNHucBRMqLjfTBhH7khla4FiM7TxpfWgCrcjfMwfe0irQRodhh3eKugA-MqxDXmwisl8QWlY1VCcSBB9ZYMBGA6LG91mBZM9cWGUVoKLJQ2fXY-9qI2axGdWR-QDy_WPbYp8oUq46a1uxnaISsMkJ2cjqqGrv__uhHto76iZIfHU_usW45X8I-apRSH1TO-AdPKeYT |
link.rule.ids | 315,786,790,1382,27957,27958,46329,46753 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtNAEB6lQaJcym9poJQ9cODi1PZ6_SNxiQJR0salilKpPSBrvZ6NAqobJc6lJyRegGfkSZhdO0GgHipuK82utNbM7H6znvkG4J3hUIuRjNctEu0EOfecOBTocKlFgdJVXJsC5_QsHF4EJ5fisgUfNrUwNT_E9sHNeIY9r42Dmwfp4z-sofOvqmvCBb4DD8jdhQ2oJlvyKAN1Gg5m16FQLNzwCrn-8XbpXbjyb5hq75nBY_iy2WGdXvKtu67yrrr9h7zxfz_hCew1AJT1aot5Ci0sn8HDtPnF_hx-XKV0-bOVSWyv5re4YtXSPMb_-v6zxJmlCWe5yWSvmDIWs2TVDbvGa9pHaSblpk8Tm056ozFrmgCxBY9Z2js_JTGTJO0PP5_T2FatEOJlHyeCrRdLnDW9xF7AxeDTtD90mk4NjgoSlzsE83IklQuZBL4q4iLASHqxEj6q0I_cUHNXU3DnCeULjahl4YYF-l4uo1zxkO9Du7wp8QCYDOnIiVB7SawJ3GiZYBx4qJVGFSHyDhxuNJY17rbKTJBGOIvAXQde1lrMFjVbR-YHhtIvFh14b3WxFdSEzX5GSsisErLRSd8OXt1_6lvYHU7TcTYenZ2-hkcEp0wupOOJQ2hXyzW-IchS5UfWMn8Dt7PqNQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NattAEB7SFEIvbfrv5qd7yKEXOdKudiXRk7Fj7CROjEkghYJYrWZDWqIYW77kVOgL5BnzJJmVZIeUHkpvC7MLK2Zm95vVzDcAe45DLUYyXj9PrBdmIvBiJdET2soctW-EdQXOoxM1OA8PL-TFGnxd1sLU_BCrBzfnGdV57Rx8mtv9R9LQqx-m7aIF8Qyeh0pwZ9K9yYo7yiGdhoLZ9ygSU0taIZ_vr5b-DVY-RanVNdN_Bd-XG6yzS362F2XWNrd_cDf-5xdswssGfrJObS-vYQ2LN7Axan6wv4Xf30Z09bO5S2svr25xzsqZe4q__3VX4GVFEs4yl8deMuPsZcbKG3aN17SNwk3KXJcmdjbpDI9Z0wKITUXMRp3xEYmZJml3cDqmcVWzQniX9SaSLaYzvGw6ib2D8_7BWXfgNX0aPBMmvvAI5GVICpc6CbnJ4zzESAexkRyN4pGvrPAthXaBNFxaRKtzX-XIg0xHmRFKvIf14qbAj8C0ogMnQhsksSVoY3WCcRigNRZNhChasL1UWNo42zx1IRqhLIJ2LfhQKzGd1lwdKQ8doV8sW_ClUsVKUNM185SUkFZKSIeH3Wrw6d-nfoaNca-fHg9PjrbgBWEplwjpBXIb1svZAncIr5TZbmWXDxrr6OQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=YM155+sensitizes+triple-negative+breast+cancer+to+membrane-bound+TRAIL+through+p38+MAPK-+and+CHOP-mediated+DR5+upregulation&rft.jtitle=International+journal+of+cancer&rft.au=Pennati%2C+Marzia&rft.au=Sbarra%2C+Stefania&rft.au=De+Cesare%2C+Michelandrea&rft.au=Lopergolo%2C+Alessia&rft.date=2015-01-15&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=0020-7136&rft.eissn=1097-0215&rft.volume=136&rft.issue=2&rft.spage=299&rft_id=info:doi/10.1002%2Fijc.28993&rft.externalDBID=NO_FULL_TEXT&rft.externalDocID=3474432531 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0020-7136&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0020-7136&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0020-7136&client=summon |